Phase 1/2 Study of CISH Inactivated TILs in the Treatment of NSCLC
Status:
Not yet recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
A clinical trial to assess the safety and efficacy of genetically-engineered Tumor
Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been
inhibited using CRISPR gene editing for the treatment of Metastatic Non-small Cell Lung
Cancer (NSCLC).